← Back to Search

Movement Tracking Devices for Cancer Patients on Chemotherapy

N/A

Waitlist Available

Led By Jorge Nieva

Research Sponsored by University of Southern California

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Able to ambulate without an assistive device

Undergoing at least 2 planned cycles of highly emetogenic chemotherapy defined according to the Hekseth scale

Timeline

Screening 3 weeks

Treatment Varies

Follow Up day 21 (visit 2)

Awards & highlights

Study Summary

This trial uses movement tracking devices to see if they can help optimize and monitor physical activity for cancer patients who are undergoing chemotherapy during the day.

Who is the study for?

This trial is for solid tumor patients undergoing chemotherapy who can consent, wear tracking devices, and report symptoms for up to 60 days. They must read English, Spanish or Mandarin, use a smartphone and wristband, be on specific chemo cycles without assistive walking devices. Excluded are those missing limbs, with symptomatic brain metastases or severe movement disorders.Check my eligibility

What is being tested?

The study tests if movement tracking devices like Microsoft Kinect 2 and Band 2 can help optimize physical activity monitoring in solid tumor patients receiving day chemotherapy. It involves wearing sensors and using technology to provide daily health data.See study design

What are the potential side effects?

There may not be direct side effects from the interventions as they involve non-invasive tracking of physical activity. However, discomfort or skin irritation from wearing the devices could occur.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I can walk on my own without needing help from devices.

Select...

I am scheduled for at least 2 cycles of strong chemotherapy.

Select...

I have a solid tumor and am receiving treatment to relieve symptoms or prevent cancer return.

Select...

I can use a smartphone and a wearable wristband.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ day 21 (visit 2)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~day 21 (visit 2)

This trial's timeline: 3 weeks for screening, Varies for treatment, and day 21 (visit 2) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Percent of patients who achieve "data capture success" defined as having both PRO data and accelerometry data transmitted to the investigators in 80% of the observation days

Percentage of patients whose wearable activity monitor provides movement data

Secondary outcome measures

Change in weight over time

Other outcome measures

Patient in-office activity performance time assessed by Microsoft Kinect 2

Presence of circulating tumor cells in blood

Sum of inpatient and outpatient hospital encounters

Trial Design

1Treatment groups

Experimental Treatment

Group I: Observational (physical activity, accelerometer, PROs)Experimental Treatment4 Interventions

Patients perform 2 physical activities in an exam room that are recorded using a Microsoft Kinect 2 stationary movement tracking device on days 1 and 21. The first activity is rising from a chair, walking 10 feet, and returning to the chair. The second activity is moving from the chair to the step-up examination table. Patients also wear a movement tracking wristband, Microsoft Band 2, around their wrist, complete a smartphone application based PRO questionnaire, and weigh themselves daily for 60 days.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Accelerometer

2020

Completed Phase 2

~460

Telephone-Based Intervention

2017

Completed Phase 2

~3360

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,636 Previous Clinical Trials

40,929,508 Total Patients Enrolled

3 Trials studying Tumors

1,244 Patients Enrolled for Tumors

University of Southern CaliforniaLead Sponsor

904 Previous Clinical Trials

1,596,307 Total Patients Enrolled

Jorge NievaPrincipal InvestigatorUniversity of Southern California

Media Library

Physical Activity Measurement Clinical Trial Eligibility Overview. Trial Name: NCT03098277 — N/A

Physical Activity Measurement 2023 Treatment Timeline for Medical Study. Trial Name: NCT03098277 — N/A

Tumors Research Study Groups: Observational (physical activity, accelerometer, PROs)

Tumors Clinical Trial 2023: Physical Activity Measurement Highlights & Side Effects. Trial Name: NCT03098277 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies within this clinical trial?

"According to the clinicaltrials.gov website, this medical experiment has ceased enrolling participants since its last edit on August 5th 2022. Nonetheless, there are 17 alternative studies searching for volunteers as of now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy

2016. "Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03098277.